To appraise the clinical and cost effectiveness of pertuzumab within its marketing authorisation for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer.
Status In progress
Process STA pre-2018
ID number 1096

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
24 August 2017 - 22 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance